Bensignor MO, Bomberg EM, Bramante CT, et al. - Utilizing data from the ellipse trial, researchers sought to evaluate the impacts of liraglutide vs placebo on body mass index (BMI) and weight parameters in children and adolescents with type 2 diabetes (T2D). The ellipse trial randomized candidates (10‐< 17 years old, BMI > 85th percentile, T2D, glycated haemoglobin 7.0%‐11.0% [if diet‐ and exercise‐treated] or 6.5% to 11.0% [if treated with metformin, basal insulin or both]) to liraglutide or placebo. A total of 134 participants were involved. In children and adolescents with T2D, liraglutide was correlated with statistically significant declines in BMI/weight parameters at week 52, but not at week 26, as compared with placebo.